Cardiff Oncology to Present at Upcoming Investor Conferences

Core Insights - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [4] - The company will present at two upcoming investor conferences, highlighting its commitment to engaging with the investment community [1] Conference Details - At the B. Riley Securities Precision Oncology & Radiopharma Conference, CEO Mark Erlander will participate in a panel discussion on improving responses in colorectal cancer on February 28, 2025, in New York City [2] - The TD Cowen 45th Annual Health Care Conference will feature a company presentation by CEO Mark Erlander on March 5, 2025, at 11:50 AM ET in Boston, MA, with a live webcast available [3] Company Overview - Cardiff Oncology's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care therapies for RAS-mutated metastatic colorectal cancer and other cancers [4] - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard therapies [4]